American Regent Initiates Recall of Vasopressin Injection Lots

The FDA has announced American Regent is conducting a nationwide voluntary recall of 17 lots of vasopressin injection, USP, multiple-dose vials, due to sub-potency.

Advertisement

 

The recall includes five lots of vasopressin injection, USP 20 units/mL (200 units/10mL), 10 mL multiple-dose vials; 11 lots of vasopressin injection, USP 20 units/mL, 1 mL multiple-dose vials; and one lot of vasopressin injection, USP 10 units/0.5 mL, 0.5 mL multiple-dose vials, according to an American Regent news release.

 

The recall was initiated by American Regent because some vials may not maintain potency throughout their shelf-life.

 

Vasopressin injection, USP is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus.

 

Read the American Regent news release, hosted by FDA, about the vasopressin injection recall.

 

Related Articles About Recalls:

Recalled Alcohol Wipes Still Being Used

Infusion Pumps Plagued by Multiple FDA Recalls

FDA Announces Recall of Anesthesia Breathing Circuits

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.